The deal size was increased to $225M in common stock from $200M in common stock. Morgan Stanley, JPMorgan, TD Cowen and Stifel acted as joint book running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics Announces Pricing of $225 Million Public Offering
- Kymera Therapeutics Announces Proposed Public Offering
- Kymera Therapeutics price target raised to $45 from $34 at Morgan Stanley
- Kymera Therapeutics price target raised to $38 from $30 at Wells Fargo
- Kymera Therapeutics price target raised to $60 from $46 at H.C. Wainwright